Most people living with HIV today keep the virus in check with a daily pill, and a growing number use long-acting shots. A small new study points to a different kind of option: two lab-made antibodies, given together as an infusion once every eight weeks, with no daily HIV pills in between. The results were presented at the HIV Drug Therapy Glasgow 2026 congress on November 10 and published the same day in The Lancet HIV.

The regimen, called TMB-365/TMB-380, is made by TaiMed Biologics. It is investigational, it is not approved by the FDA, and this was an early-stage study in only 20 people. Here is what it found and why it matters.

How the two antibodies work

According to aidsmap's report from the congress, the two antibodies block HIV from entering immune cells from opposite sides:

• TMB-365 attaches to CD4, the protein on immune cells that HIV uses as its way in. The virus can still latch on, but the antibody blocks the next steps it needs to get inside. aidsmap compares it to holding a door shut after a key is already in the lock. It is related to ibalizumab, an older antibody already approved for some people with drug-resistant HIV.
• TMB-380 is a broadly neutralizing antibody that targets the virus itself. It covers the part of HIV's outer protein that normally binds to CD4, like covering the key so it cannot fit.

Because one antibody targets the person's cells rather than the virus, the researchers say it may be harder for HIV to escape by mutating. That is a theory to test in larger studies, not a proven result.

What the study found

The phase 2a part of the study took place at six clinics in the United States. Participants already had an undetectable viral load on daily pills, a CD4 count above 350 and no history of treatment failure. They stopped their usual HIV medicines on the day of their first infusion and then received both antibodies together, in a roughly one-hour infusion, every eight weeks for 24 weeks. Unlike many antibody studies, people were not first screened to see whether their virus was sensitive to the antibodies.

As reported by aidsmap and in TaiMed's November 10 announcement:

• Viral suppression: at 24 weeks, 16 of the 17 participants with results (94%) had a viral load below 50 copies. The one other person was at 59 copies. Counting all 20 people who started, 16 (80%) were suppressed at week 24.
• No treatment failures: no one met the study's definition of virological failure.
• Short "blips": three participants had temporary viral load rises to about 200 to 300 copies before returning to suppression. All three weighed more than 90 kg (about 200 pounds) and had lower levels of TMB-365, which suggests body weight may matter for dosing.
• Side effects: there were no serious side effects. Mild to moderate effects included rash, tiredness and headache. Two people stopped because of a rash. CD4 counts stayed stable.
• How people felt: participants rated the antibody regimen better for convenience, flexibility and fit with their lifestyle.

After the 24 weeks, everyone went back to their usual oral treatment.

Why it matters for dating and relationships

For many people, the hardest part of HIV is not the medicine itself but what it represents: a daily routine to manage, a pill bottle to explain, and a reminder of the diagnosis. That is why research into longer-acting options keeps drawing attention. We covered a similar theme this week in our report on a weekly HIV pill that meant fewer daily reminders of HIV.

An antibody infusion every eight weeks would not suit everyone. It means regular clinic visits, staff time and an hour in a chair. Long-acting injections of cabotegravir plus rilpivirine, already approved and given monthly or every two months, offer a non-daily option today. Dr. Martin Markowitz, the study's lead author, told aidsmap the antibodies could one day help people ageing with HIV who take several other medicines, because antibodies are processed differently from standard HIV drugs and may raise fewer drug-interaction concerns. You can read more about how long-acting shots perform outside trials in our coverage of real-world results for long-acting HIV shots.

What matters most for partners has not changed. Any treatment that keeps a person's viral load undetectable means HIV cannot be passed on through sex. That is U=U (Undetectable = Untransmittable), and you can learn what U=U means for dating and relationships in our explainer. Antibodies are also being studied for prevention; see our report on the VRC01 prevention antibody trials.

Whether and when to tell a partner about your status is your decision, and disclosure laws vary by state. If you are getting ready for that conversation, our guide to HIV disclosure while dating can help.

Important caveats

• Very small and short: 20 participants, followed for 24 weeks. Dr. Markowitz told aidsmap that the study "does not establish that screening is unnecessary" and cannot yet show the true rate of treatment failure or how resistance might develop over time.
• No comparison group: the phase 2a study did not compare the antibodies with standard daily treatment.
• Not a diverse group: all participants were men aged 24 to 67, and three quarters were White. Results in women and other groups are not known.
• Immune reaction to the treatment: one participant developed low levels of antibodies against the treatment antibodies, with no effect in this study. aidsmap notes that a stronger reaction of this kind could reduce how well such treatments work.
• Not approved: TMB-365/TMB-380 is investigational. A larger, one-year phase 2b trial comparing it with oral treatment, using weight-based dosing of TMB-365, is under way.

The bottom line

An all-antibody HIV treatment given every eight weeks kept HIV suppressed in most people in a small early study, with no treatment failures and no serious side effects. It is not available outside clinical trials, much larger studies are needed, and today's daily pills and long-acting shots remain proven ways to stay undetectable. Never stop or change HIV treatment on your own. If your current routine feels like a burden, talk with your HIV care provider about the options that fit your health and your life.

Want to meet people who already understand? Explore HIV dating on MeetPositives or read our guide to dating after an HIV diagnosis.

Sources

• aidsmap. "A pair of antibodies keeps HIV undetectable by 'bolting the door and masking the key'." HIV Glasgow 2026 coverage, November 11, 2026.
• Markowitz M, et al. "Safety, pharmacokinetics, and antiviral activity of a combination of TMB-365 and TMB-380 in people living with HIV suppressed with antiretroviral therapy in the USA: a phase 1b/2a, open-label, dose-escalation study." The Lancet HIV, published online November 10, 2026. doi:10.1016/S2352-3018(26)00148-7.
• Markowitz M, et al. "A 24-week phase 2a maintenance study of TMB-365/TMB-380 q8w in people with suppressed HIV-1 infection." HIV Glasgow 2026, abstract O31.
• TaiMed Biologics. "TaiMed Biologics Announces Publication in The Lancet HIV of Phase 1b/2a Study of Long-Acting Dual-Antibody HIV Maintenance Regimen TMB-365/TMB-380." News release, November 10, 2026.

This article is for general information only and is not medical or legal advice. It does not create a doctor-patient relationship. Talk with a licensed health care provider about your own situation. Laws vary by state; for legal questions, talk with a licensed attorney. This article does not recommend or promote any product.